Mindfulness based cognitive therapy versus treatment as usual in adults with attention deficit hyperactivity disorder (ADHD) by Janssen, L. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/153395
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
STUDY PROTOCOL Open Access
Mindfulness based cognitive therapy versus
treatment as usual in adults with attention
deficit hyperactivity disorder (ADHD)
Lotte Janssen1* , Cornelis C. Kan1, Pieter J. Carpentier2, Bram Sizoo3, Sevket Hepark1, Janneke Grutters4,
Rogier Donders4, Jan K. Buitelaar5 and Anne E M Speckens1
Abstract
Background: Adults with attention deficit hyperactivity disorder (ADHD) often present with a lifelong pattern of
core symptoms that is associated with impairments of functioning in daily life. This has a substantial personal and
economic impact. In clinical practice there is a high need for additional or alternative interventions for existing
treatments, usually consisting of pharmacotherapy and/or psycho-education. Although previous studies show
preliminary evidence for the effectiveness of mindfulness-based interventions in reducing ADHD symptoms and
improving executive functioning, these studies have methodological limitations. This study will take account of
these limitations and will examine the effectiveness of Mindfulness Based Cognitive Therapy (MBCT) in further
detail.
Methods/design: A multi-centre, parallel-group, randomised controlled trial will be conducted in N = 120 adults
with ADHD. Patients will be randomised to MBCT in addition to treatment as usual (TAU) or TAU alone.
Assessments will take place at baseline and at three, six and nine months after baseline. Primary outcome measure
will be severity of ADHD symptoms rated by a blinded clinician. Secondary outcome measures will be self-reported
ADHD symptoms, executive functioning, mindfulness skills, self-compassion, positive mental health and general
functioning. In addition, a cost-effectiveness analysis will be conducted.
Discussion: This trial will offer valuable information about the clinical and cost-effectiveness of MBCT in addition to
TAU compared to TAU alone in adults swith ADHD.
Trial registration: ClinicalTrials.gov NCT02463396. Registered 8 June 2015.
Background
Attention Deficit Hyperactivity Disorder (ADHD) is a
common neurodevelopmental disorder with a high
persistence into adulthood. Results of a meta-analysis of
six studies indicated the pooled prevalence of adult
ADHD according to DSM-IV criteria to be 2.5 % (95 % CI
2.1-3.1) [1]. In a Dutch population the prevalence of adult
ADHD has been found to be 2.1 % (95 % CI 1.4-3.0) [2].
Patients with ADHD show a persistent pattern of inatten-
tion and/or hyperactivity-impulsivity, which leads to
impairment of functioning in two or more areas in daily
life, for example at work, school and/or home. These
impairments have a substantial personal and economic
impact. A recent study shows that ADHD is associated
with increased mortality, mainly driven by deaths from
unnatural causes like accidents [3]. Furthermore, adult
ADHD is related to higher levels of unemployment and
those who are employed often experience workplace im-
pairment and reduced productivity [4]. In an international
population ADHD is associated with 22 days of excess lost
role performance among employees a year [5] and with el-
evated risk of high number of days out of role (OR = 2.6,
95 % CI 2.0-3.5) [6]. Results of a recent survey in a Dutch
general population sample showed that adults with ADHD
had significantly more functional impairments and an in-
creased health care use than persons without ADHD [2].
The vast majority of ADHD patients in the Netherlands
is offered stimulant medication after or parallel to psycho-
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education on ADHD. In accordance with the NICE
guideline on ADHD [7] stimulants are the first-line
treatment for adults as part of a comprehensive treat-
ment programme that addresses psychological, behav-
ioural and educational or occupational needs. The
pooled effect size of stimulant medication in reducing
ADHD symptoms was in the medium-to-high range [8].
Stimulants demonstrated efficacy and they seemed to im-
prove work productivity [9]. Moreover drug treatment in
ADHD seemed to have a protective effect on the risk of
criminality [10] and suicidal behaviour [11]. Although
pharmacological treatment has thus shown to be effective
in reducing ADHD symptoms and to have beneficial
effects, about 10-30 % of adults with ADHD do not
adequately respond to stimulants [12] and often report
adverse effects like decreased appetite, dry mouth, tension
or jitteriness [13], which can lead to discontinuation. It
has also been found that these patients were compliant
with medication for rather a brief period (M= 49.5 days),
and the average persistence with medication was less than
a year (M = 199.9 days) [14]. Besides, some patients with
ADHD are not willing to take medication at all. Further-
more, the evidence for long-term effects of stimulants is
sparse [15]. Therefore, there is a strong need for evidence-
based psychosocial interventions, as an addition to or an
alternative for pharmacological treatment of adult ADHD.
The NICE guideline recommends group Cognitive Be-
havioural Therapy (CBT) for adults with ADHD whose
response to medication is insufficient, who have diffi-
culty adhering to drug treatment or who are not willing
to use medication. Some studies have shown evidence
for the efficacy of treatment with CBT in adults with
ADHD, particularly when combined with medication
[16]. For example, Safren et al. [17] found support for
the effectiveness of individual CBT for patients with
ADHD, who are treated with medication but continue to
have residual symptoms, compared to a time-matched
comparison treatment. Another study of Solanto et al.
[18] showed that meta-cognitive group therapy, which is
a cognitive-behavioural intervention, provides significant
benefit to patients with ADHD with respect to the sever-
ity of ADHD symptoms in comparison with supportive
group therapy. However, more controlled research stud-
ies are required. Another promising psychosocial inter-
vention for patients with ADHD is Mindfulness-Based
Cognitive Therapy (MBCT), which combines methods of
CBT and mindfulness meditation. Mindfulness is defined
as paying attention in a particular way: on purpose, in
the present moment, and non-judgmentally [19]. MBCT
is usually offered in a group format, consisting of 8
weekly sessions of 2,5 hours and a silent day [20], which
may be more cost-effective than individual treatment. In
recent years, mindfulness based therapy, such as MBCT,
has been demonstrated to reduce anxiety, depression
and stress in a wide range of psychiatric disorders [21], in-
cluding current anxiety and depressive disorders [22]. Fur-
thermore, there is evidence that mindfulness meditation
strengthens attention regulation [23–25] and improves
some executive functions [26] in healthy subjects. Al-
though these studies were not focused on patients with
ADHD and replication studies need to be carried out, this
is promising evidence in the search for an effective non-
pharmacological treatment for this patient group.
A few studies on the effectiveness of mindfulness training
for adults with ADHD have so far been conducted, two un-
controlled pilot studies [27, 28] and two randomised con-
trolled trials (Hepark, Janssen, De Vries, Schoenberg, Kan,
& Speckens: The effects of Mindfulness-Based Cognitive
Therapy on core sympotms and executive functioning in
adults with ADHD: a preliminary randomised controlled
trial, submitted) [29]. The studies of Zylowska et al. [27] and
Mitchell et al. [29] used the 8-week Mindful Awareness
Practices (MAPs) for ADHD programme [30], while our
own group [28] (Hepark et al., submitted) used an adapted
and extended MBCT programme. All of these studies ob-
served a substantial reduction of primary ADHD symptoms,
and the effect of mindfulness training on ADHD symptoms
seems to be mediated by an increase of mindfulness skills
(Hepark et al., submitted). Moreover, improvements of ex-
ecutive functioning (Hepark et al., submitted) [29] and
emotion regulation [29] were reported. In both pilot stud-
ies [27, 28] improved executive control was observed
using neuropsychological tasks, but this was not replicated
in the two randomised controlled trials. Empirical evi-
dence regarding the reduction of secondary symptoms,
like depressive and anxiety symptoms and general func-
tioning, is mixed [27, 28] and (Hepark et al., submitted).
Possibly, this is partially due to baseline differences in
levels of secondary symptoms in the various samples.
The results of the above mentioned studies support the
feasibility and efficacy of mindfulness training as a treatment
for adults with ADHD and encourage further research. This
approach offers a novel and potentially useful tool in the
multimodal treatment of ADHD. Previous studies are con-
ducted in one centre and lack a follow-up period. Some of
them are small [27–29], uncontrolled [27, 28] and lack
blinding [27–29]. The proposed study is the first properly
powered randomised controlled multi-centre study, which
includes blinded outcome assessments, a longer term
follow-up period and assessment of cost-effectiveness.
Aims of the trial
The primary aim of this study is to investigate effective-
ness of MBCT in addition to Treatment As Usual (TAU)
versus TAU alone in adults with ADHD. We expect that
MBCT can improve ADHD symptoms and overall func-
tioning in two ways: a) by strengthening their attention
regulation and executive functioning, resulting in a greater
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reduction of ADHD symptoms rated by a blinded clinician
(primary outcome) and self-reported ADHD symptoms
and a greater improvement of executive functioning
(secondary outcomes); and b) by extending their reper-
toire of coping strategies to deal with core symptoms and
functional impairments, resulting in a greater improve-
ment of general functioning, positive mental health and
self-compassion (secondary outcomes).
Other aims of the study are to assess whether MBCT is
a cost-effective intervention compared to TAU in patients
with ADHD from a societal perspective and to assess the
financial consequences of implementing mindfulness
training in patients with ADHD from different perspec-
tives (e.g. societal, health care, health insurance and
patient). We expect that the implementation of this inter-
vention will result in a reduction of medical and societal
costs in the MBCT group compared to the TAU group.
Furthermore, in order to gain insight in the working mech-
anisms of mindfulness, we will investigate whether possible
clinical effects of MBCT can be attributed to changes in
mindfulness skills, self-compassion and adherence to MBCT.
Methods/design
Study design
The design of the study is multi-centre, parallel-group,
randomised controlled superiority trial. Patients will be
randomised to MBCT in addition to TAU or TAU alone.
The study protocol has been ethically approved by CMO
Arnhem-Nijmegen for all participating centres and regis-
tered under number 2014/206.
Participants
The study population will consist of adults with ADHD.
To enhance generalisability, the study is conducted in
three different mental health centres for patients with
ADHD in the south-east of the Netherlands: the Depart-
ment of Psychiatry of the Radboudumc in Nijmegen, the
Reinier van Arkel Group in the Jeroen Bosch hospital in ‘s
Hertogenbosch and Dimence in Deventer. Each centre
has a specialized outpatient clinic for adults with develop-
mental disorders, like ADHD.
Eligibility criteria
We will include patients of 18 years and older who meet
the following criteria: a) a primary diagnosis of ADHD,
according to the criteria of Diagnostic and Statistical
Manual of Mental Disorders – 4th edition (DSM-IV-TR)
[31] based on a structured Diagnostic Interview for
ADHD, in adults (DIVA) [32]; and b) capable of filling
out questionnaires in Dutch. Exclusion criteria will be: a)
depressive disorder with psychotic symptoms or suicidal-
ity; b) current manic episode; c) borderline or antisocial
personality disorder; d) substance dependence; e) autism
spectrum disorder; f ) tic disorder with vocal tics; g)
learning difficulties or other cognitive impairments; and
h) former participation in a MBCT or MBSR course or
workshop of more than two hours’ duration. We will use
a psychiatric structured diagnostic interview (MINI-Plus)
[33] to establish whether patients meet the above men-
tioned exclusion criteria a, b and d. To assess the third ex-
clusion criterion, screening lists for borderline and
antisocial personality disorders based on the Structured
Clinical Interview for DSM-IV Axis II Disorders (SCID-II)
[34] will be administered. In patients meeting five or more
criteria on one or both of the lists, the entire interview for
borderline and/or antisocial personality disorder of the
SCID-II will be conducted.
Procedure and treatment allocation
Recruitment will take place in different ways: by referral
via the specialist outpatient clinics of the three participat-
ing centres and by self-selection. Currently and formerly
treated patients with ADHD at the Radboudumc, the
Reinier van Arkel Groep and Dimence will be informed
about the study by their attending clinicians in various
stages of their treatment process. Patients will also be re-
cruited by self-selection by media advertisements, for ex-
ample through the website of the Dutch association of
adults with ADHD (Impuls & Woortblind) and in presen-
tations at regional thematic meetings. Interested patients
will receive an information leaflet and are invited for a
screening by telephone with the researcher or research as-
sistant to assess eligibility. If patients seem to be eligible,
they will get one to two weeks time to consider participa-
tion. Patients who chose to participate will be invited for
an interview with the researcher or research assistant in
which written informed consent will be obtained.
When the Diagnostic Interview for ADHD in adults
(DIVA) has not been conducted to diagnose ADHD
before, it will be administered by a psychologist or psych-
iatrist with relevant experience with this specific patient
group to check whether a patient indeed meets the DSM-
IV criteria for ADHD. Whenever possible the interview
will take place in the presence of a family-member, partner
or significant other to enable retrospective and collateral
information to be ascertained simultaneously.
Blinded assessments with the investigator-rated
screening version of the Conners’ Adult ADHD Rating
Scale (CAARS-INV) will be obtained by trained psychi-
atrists or specialist registered nurses (in training) at
baseline, 3, 6 and 9 months after baseline. The 6 and
9 months follow-up assessments will take place by
phone. Self-report questionnaires will be administered
at all of the above mentioned four time points. In order
not to disadvantage patients randomised to the TAU
group, we will offer them MBCT after completion of
the study at 9 months follow-up.
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Patients will be able to use medication for ADHD such
as psycho-stimulants, during the entire study and they
will not be withheld from other psychosocial treatments
they might be offered. Concurrent interventions will be
closely monitored and registered. See Fig. 1 for a flow-
chart of the recruitment and study procedure.
Randomisation
Randomisation will be computerised and be stratified for
centre. Block randomisation with varying predefined block
sizes is used combined with minimisation. Block random-
isation will be dominant over minimisation. The random-
isation will be minimised taking account of: a) use of
medication for ADHD (medication versus no medication);
b) past participation in a psycho-education training
(psycho-education versus no psycho-education); c) gender
(male versus female); and d) subtype ADHD (combined,
hyperactive-impulsive, inattentive and not otherwise spe-
cified). The researcher will be blind for the block sizes.
Blinding
Blinded assessments by a psychiatrist or specialist nurse
with the investigator-rated screening version of the
Conners’ Adult ADHD Rating Scale (CAARS-INV) will
take place at baseline and 3, 6 and 9 months after base-
line. At baseline patient nor interviewer will know in
which group the patient will be placed. To ensure that
the interviewers stay blind during the other time points
of assessment, patients will be instructed at the research
interview not to share information about allocation with
the interviewer. At the beginning of each assessment,
the interviewer will repeat this instruction.
Outcome measures
Selection and diagnostic measures
The Diagnostic Interview for ADHD in adults (DIVA)
[32] is a structured interview used in our study to diag-
nose ADHD in adults. The first part consists of the
DSM-IV criteria of ADHD in childhood and adulthood
Fig. 1 Of the recruitment and study procedure
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and the second part is to determine impairment in five
domains (education and work, relationships and family
life, social contacts, leisure time and self-confidence) in
both life periods. Whenever possible, the information
provided by the patient is supplemented by collateral in-
formation from a family member or partner and by
school reports.
Primary outcome measure
ADHD symptoms (investigator-rated) We will use the
investigator-rated screening version of the Conners’
Adult ADHD Rating Scale (CAARS-INV: SV) [35] by a
blinded clinician to assess DSM-IV criteria symptoms as
well as specific manifestations of ADHD, such as mood
lability. This interview consists of 30 items, which are
rated on a 4-point Likert scale. Ratings can be organised
in three subscales: Inattention, Hyperactivity/Impulsivity,
and the ADHD index. All subscales have shown good
internal consistency and inter-rater reliability, as well as
sensitivity to treatment outcome [36]. Cronbach’s α
coefficients vary from .74 to .94 and intraclass correla-
tions between investigator-ratings and self-ratings
ranged from .45 to .87 [36].
Secondary outcome measures
ADHD symptoms (self-reported) The self-report ver-
sion of the Conners’ Adult ADHD Rating Scale (CAARS-
S:SV) [35] will be used to assess self-reported ADHD
symptoms. This questionnaire consists of 30 items, which
are rated on a 4-point Likert scale, and has the same
structure as the investigator version. The internal
consistency is comparable with that of the investigator
version and Cronbach’s α coefficients vary from .76 to .95
at different time points [36].
Executive functioning The self-report version for
adults of the Behaviour Rating Inventory of Executive
Function (BRIEF-A) [37] will be used to measure
executive functioning in daily life. This questionnaire
consists of 75 items on a 3-point Likert scale and has
nine subscales: Inhibit, Shift, Emotional Control, Self-
monitor, Initiate, Working Memory, Plan/Organise,
Task Monitor, and Organization of Materials. Three
validity scales are included: Negativity, Infrequency,
and Inconsistency. For the Dutch version of the BRIEF-
A internal consistency varies with Cronbach’s α coeffi-
cients ranging from .70 to .89 and test-retest reliability
was found to be .70 or higher [38].
Mindfulness skills We will use the short form of the Five
Facet Mindfulness Questionnaire (FFMQ-SF) [39, 40] to
measure mindfulness skills. This self-report questionnaire
consists of 24 items which are rated on a 5-point Likert
scale. Five facets of mindfulness are distinguished: Observ-
ing, Describing, Acting with Awareness, Non-judging, and
Non-reactivity. The Dutch version of the FFMQ-SF has
been shown to be a reliable instrument which is sensitive
to change in a population with depressive and anxiety
symptoms. Cronbach’s α coefficients between .75 and .87
have been found [39].
Self-compassion The short form of the Self-Compassion
Scale (SCS-SF) [41, 42] will be used to measure self-
compassion. This instrument consists of 12 item based on
a 7-point Likert scale and measures six components of
self-compassion: Self-kindness, Self-judgement, Common
Humanity, Isolation, Mindfulness and Over-identification.
The shortened scale shows a near-perfect correlation with
the original Self-Compassion Scale. In a Dutch population,
Cronbach’s α coefficient for the full scale is .87 and the
coefficients for the subscales of the SCS-SF vary from .55
to .81. The internal consistency of one of the components
(Self-kindness) was relatively low [41].
Positive mental health The short version of the Mental
Health Continuum (MHC-SF) will be used to measure
positive mental health [43, 44]. This self-report question-
naire has 14 items which are scored on a 6-point Likert
scale and three subscales: Emotional, Psychological and
Social. The Dutch version of this instrument has a good
internal reliability with Cronbach’s α coefficients varying
between .74 and .89 [43].
General functioning We will use the Outcome Ques-
tionnaire (OQ 45.2) [45] to measure general functioning.
This self-report questionnaire consists of 45 items and
three subscales: Symptom Distress, Interpersonal Rela-
tions, and Social Role. The items are scored on a 5-point
Likert scale. Cronbach’s α coefficients ranged from .70 to
.93 and test-retest reliability with Pearson’s r varied from
.78 to .84 [45]. The Dutch version of the OQ has com-
parable psychometric properties with Cronbach’s α coef-
ficients between .69 and .93 and Pearson’s r from .70 to
.83 in a clinical population [46].
Cost-effectiveness
Resource use Resource use will be collected and calcu-
lated with the latest version of the Trimbos/iMTA ques-
tionnaire for costs associated with psychiatric illness
(TiC-P) [47]. This self-report instrument consists of two
parts: a) healthcare consumption including contacts
within the mental and the general healthcare sector and
the use of medication; b) productivity loss. The recall
period for the TiC-P is three months for healthcare
consumption and one month for productivity loss. Test-
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retest reliability is satisfactory to almost perfect for most
items related to healthcare consumption and satisfactory
for items on absence from work and presenteeism. Cohen’s
kappa values range from .49 to .84 [48].
Quality Adjusted Life Years (QALYs) health gains We
will use the 12-item Short Form (SF-12) Health Survey
[49], a shortened version of the SF-36 [50], which is a
widely used instrument for measuring health status to
calculate QALYs. The SF-12 is a self-report question-
naire with eight domains divided in two components: a
physical component summary (Physical Functioning,
Role Limitations due to Physical Problems, Bodily pain,
General Health) and a mental component summary
(Role Limitations due to Emotional Problems, Mental
Health, Social Functioning, Vitality). Acceptable levels of
internal consistency have been found, with Cronbach’s α
coefficients of .84 for the physical component and .81
for the mental component [51]. Test-retest reliability
coefficients of .89 for the physical component and .76
for the mental component have been measured in a US
population [49].
Process measure
Adherence to MBCT During the nine weeks of partici-
pation in the MBCT group, we will assess adherence to
mindfulness exercises with a calendar on which patients
fill out total minutes of formal (e.g. sitting meditation)
and informal practice (e.g. mindful eating) on a daily
basis. For patients allocated to the MBCT group, we will
assess adherence during 6 and 9 months after baseline
by questions in which patients are asked to estimate
total minutes of formal and informal practice during an
average week in the last three months. To check for
compliance with the instruction to refrain from mindful-
ness training during the nine months of the study, patients
in the TAU group will be asked whether they participated
in an MBSR or MBCT course during the study at the
different time points of assessment.
Intervention
We developed a protocol primarily based on the
Mindfulness-Based Cognitive Therapy (MBCT) for recur-
rent depression [20]. We made some modifications to
make the intervention more suitable for adults with
ADHD. For example, the psycho-education sections about
depression are replaced by psycho-education about
ADHD. We also include elements of the Mindful Aware-
ness Practices for ADHD programme (MAPs) [30]. For
example, in accordance with the MAPs protocol: a) the
meditation periods are built up more gradually compared
to the regular MBCT programme; b) mindful awareness
in daily life is emphasized; and c) one session is focused
on mindful listening and speaking. Table 1 shows the con-
tent of the MBCT programme as it will be used.
The protocol has been tested in three consecutive pilot
groups of ADHD patients and has been adapted according
to their feedback. The 8-week programme will consist of
weekly sessions lasting 2.5 hours, and a silent day between
session six and seven. In addition to the group sessions,
participants will be instructed to practice six days a week
for approximately 30 min a day and complete home
practice assignments. The participants will receive a set of
CDs containing guided mindfulness exercises for home
practice ranging in length from 10 min to 45 min.
Mindfulness teachers
The MBCT will be taught by mindfulness teachers
meeting the advanced criteria of the Association of
Mindfulness Based Teachers in the Netherlands and
Flanders and the internationally agreed good practice
guidelines of the UK Network for Mindfulness-Based
Teachers http://mindfulnessteachersuk.org.uk/pdf/teacher-
guidelines-2015.pdf) which include: a) a minimum of 150 h
of education in MBSR/MBCT background and theory
including a reflection report; b) relevant professional
training; c) minimum of three years of practicing medita-
tion regularly and attending retreats; d) having attended
MBSR/MBCT as a participant; e) continued training; and
f) giving a minimum of two courses per two year. The
teachers will receive additional training in the study proto-
col at the start of the project. We will organise peer super-
vision meetings every three weeks during the intervention
phase of the trial. Intervention integrity consisting of
adherence to the original programme, the degree to which
the intervention is delivered as intended and teacher
competency, will be assessed by the Mindfulness-based
Interventions-Teaching Assessment Criteria (MBI: TAC)
[52]. Videotapes of a random selection of sessions will be
assessed by assessors who are familiar with this
mindfulness-based programme, are 'proficient' (level 5) ac-
cording to the MBI: TAC and have received training in
the use of these assessment criteria.
Sample size
The power calculation has been based on our previous
randomised controlled study consisting of 103 adults
with ADHD (Hepark et al., submitted) in which we dem-
onstrated a significant difference in post-assessment
clinician-rated ADHD symptoms (CAARS-INV) [36] be-
tween the MBCT and waitlist control group. Based on
these study results, we expect a post-treatment differ-
ence of 4 between the two groups with a standard
deviation of 7.5. Using a two-sided test with an alpha of
0.05, a power of 80 % and analyzing the data using
ANCOVA assuming the correlation between pre- and
post-assessments to be 0.5, we would need approximately
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Table 1 Content of MBCT programme for ADHD per session
Theme of the session Mindfulness exercises (Psycho-)education Homework
1. Automatic pilot - 3-min breathing space - Rationale of mindfulness for ADHD - 3-min breathing space
- Raisin exercise - Introduction in methods to integrate mindfulness in daily
life: Support, Structure and Strategy (3 S’s)
- Attention for a routine activity
- Bodyscan - Mindful eating
- Optional: bodyscan
2. Dealing with barriers - Bodyscan - Imagery exercise to demonstrate relationship between
thoughts and feelings
- 3-min breathing space
- Attention for a routine activity
- Bodyscan
- Sitting meditation with focus on breath - Exploration of application of the 3 S’s - Awareness of pleasant events
- 3-min breathing space
3. Mindfulness of the breath - Sitting meditation with focus on breath, body - Seeing exercise a) to demonstrate the difference between
observation and interpretation, b) to discuss dealing with
sensory input
- 3-min breathing space
- Floor yoga or sitting meditation
- 3-min breathing space - Exploration of pleasant events - Awareness of unpleasant events
- Floor yoga practices
- Walking meditation
4. Staying present - Sitting meditation with focus on breath, body, sounds - Exploration of unpleasant events with attention for the
interrelatedness of feelings, thoughts and bodily sensations
- 3-min breathing space
- Sitting meditation
- 3-min breathing space - Exercise focused on recognition and dealing with ADHD
core symptoms
- Awareness of top 3 ADHD symptoms
- Walking meditation
5. Allowing and letting be - Sitting meditation with focus on breath, body, sounds,
thoughts and feelings
- Reflection on intention of participating - 3-min breathing space
- Psycho-education about reacting versus responding in
stressful situations and when ADHD symptoms are severe
- Sitting meditation or standing yoga
- 3-min breathing space ‘coping’ - Awareness of communication
difficulties- Standing yoga practices
6. Mindful communication - Standing yoga practices - Exercise in mindful listening and speaking - 3-min breathing space
- 3-min breathing space - Non-verbal communication exercise - Sitting meditation or standing yoga
- Mindful listening and speaking
Silent day - Varying meditation exercises
- Silent lunch and tea break
7. Taking care of yourself - Sitting meditation with focus on breath, body, sounds,
thoughts, emotions an choiceless awareness
- Exercise on taking care of yourself by examining how to
improve balance in life
- 3-min breathing space
- Practice without CDs
- Reflect on training
- 3-min breathing space - Making an action plan
8. The rest of your life - Bodyscan - Reflection on the training
- 3-min breathing space - Maintaining practice
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45 patients per arm. Taking account for loss of power due
to drop out of 25 %, we intend to include 120 patients, 60
patients per group.
Statistical analyses
Primary analyses
Baseline socio-demographic and clinical characteristics of
the MBCT group and the TAU group will be compared to
check whether these characteristics will have been evenly
distributed by randomisation. The primary analyses will
be aimed at comparing results on the outcome measures
at three months after baseline between the MBCT group
and the TAU group, controlling for baseline levels and
possible other baseline differences between intervention
and control groups (despite randomisation).
The outcome data will be analysed and reported
according to the CONSORT guidelines and will include
both intention-to-treat analyses and per-protocol ana-
lyses with the treatment-adherent sample (patients in
the MBCT group have to attend at least four of MBCT
sessions and patients in the TAU group do not attend a
mindfulness-based programme). Percentages of improved,
recovered, unchanged and worsened patients in the inter-
vention and control groups will be provided on the basis
of predefined cut-off scores (T-score greater than 65) and
standard deviations. In addition, a Cohen’s d-type effect
size will be calculated.
In order to investigate consolidation of treatment ef-
fect at 6 and 9 months after baseline, we will study
whether there is an intervention by time interaction with
a mixed model to accommodate for repeated measures.
Such an interaction would imply that long term effects
are different from short term effects. In addition, regres-
sion models will be used to derive prediction models for
therapy outcome.
Secondary analyses
Cost-effectiveness analysis For each patient in the
MBCT and TAU group: a) costs; b) treatment response;
and c) QALYs will be collected over the study period of
nine months. Total costs for each patient will be
obtained by multiplying the resource use as measured
with the TiC-P with standard costs, based on the Dutch
guideline for costing research [53]. Overall mean and
median costs will be compared across the two groups
and where relevant, differences will be calculated inclu-
sive of 95 % confidence intervals. Treatment response
will be based on our primary outcome, the investigator-
rated version of the CAARS. QALYs will be assessed by
the SF-12. At baseline and each follow-up interval, each
patient is assigned a utility score based on the SF-12.
From these utility scores QALYs will be calculated for
each patient using the Area Under the Curve (AUC)
method. Mean and median QALYs will be compared
across the two groups and where relevant, differences
are calculated inclusive of 95 % confidence intervals.
If MBCT is more costly and more effective than TAU,
an incremental cost-effectiveness ratio (ICER) will be
calculated by dividing the extra costs by the extra effects.
ICERs are computed to obtain the costs per responder
and the costs per QALY gained. This will give an estima-
tion of the extra costs that are needed to gain one
responder or QALY. If this is below the societal willing-
ness to pay, mindfulness training is deemed cost-
effective. If one comparator is less costly and more
effective, it dominates the other and no ICER is neces-
sary to determine cost-effectiveness. If MBCT is less ef-
fective and less costly, ICERs will be calculated
representing the savings per QALY lost. Uncertainty sur-
rounding the costs, effects and ICER will be addressed
by means of bootstrapping.
Mediation analysis To gain insight in underlying work-
ing mechanism of mindfulness, we will test with a medi-
ation analysis whether possible clinical effects of MBCT
can be attributed to changes in mindfulness skills, self-
compassion and adherence to MBCT. We will follow
the approach suggested by Preacher, Hayes [54].
Discussion
Adult ADHD has a substantial personal and economic
impact and consequently there is a high need for
evidence-based treatments for this patient group. Al-
though pharmacotherapy has shown to be effective in
reducing ADHD symptoms and its economic impact,
there is a call for psychosocial interventions to offer in
addition to pharmacotherapy or as an alternative treat-
ment. At this moment research examining the effective-
ness of psychosocial interventions for adult ADHD is
still in its infancy. Mindfulness training, such as MBCT,
is a promising psychosocial intervention, which can be
offered in a group format. Considered from an economic
perspective, this is an advantage over treatment on indi-
vidual basis. Previous studies support the feasibility of
mindfulness training for this patient group and provide
preliminary, but consistent evidence that this interven-
tion reduces ADHD symptoms and improves executive
functioning. However, the methodology of these studies
is limited by single-centre enrolment [27–29], and
(Hepark et al., submitted) lack of follow-up periods [27–29],
and (Hepark et al., submitted) small sample sizes [27–29],
lack of a control group [27, 28] and lack of blinded
assessments [27–29]. Our study will take account of
these limitations and will examine the effectiveness of
MBCT in adults with ADHD in further detail.
To our knowledge, this is the first properly powered
randomised controlled study in this field, that contains
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blinded outcome assessments and an intention-to-treat
analysis. Besides, a follow-up period with a length of six
months after the end of treatment is included to consider
potential long-term effects of MBCT. To enhance general-
isability, this study is conducted in three different mental
health centres with expertise in treating adults with
ADHD. Additionally, cost-effectiveness will be assessed to
evaluate whether MBCT is a cost-effective intervention
compared to the treatment as usual and to examine the fi-
nancial consequences of implementing this intervention.
This trial will offer valuable information on whether MBCT
has an effect on clinician-rated and self-reported ADHD
symptoms, executive functioning, general functioning, posi-
tive mental health, self-compassion and medical and soci-
etal costs in comparison to treatment as usual.
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